Guard Therapeutics International AB (SE:GUARD)
:GUARD
Want to see SE:GUARD full AI Analyst Report?
GUARD Stock Chart & Stats
kr1.38
-kr0.80(-4.00%)
At close: 4:00 PM EST
kr1.38
-kr0.80(-4.00%)
Day’s Range― - ―
52-Week Rangekr0.88 - kr27.00
Previous CloseN/A
Volume1.94K
Average Volume (3M)44.15K
Market Cap
kr31.26M
Enterprise Value-kr10.34M
Total Cash (Recent Filing)kr40.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding20,167,631
10 Day Avg. Volume59,609
30 Day Avg. Volume44,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No DebtConsistent lack of debt reduces refinancing pressure and fixed interest obligations, preserving financial flexibility. Over the next 2–6 months this durable feature lowers immediate solvency risk and gives management more options to prioritize R&D spending or time fundraising without mandatory debt servicing.
A1M Platform FocusA clear scientific focus on the A1M kidney-protective protein builds a specialized pipeline and clinical rationale in kidney disease. That platform orientation supports durable R&D direction, potential differentiation in a niche therapeutic area, and clearer go-to-market pathways if clinical milestones are met.
Lean WorkforceA very small headcount suggests low fixed overhead and the ability to operate with outsourced R&D or partnerships, which can extend runway per funding round. This structural lean cost base is durable and helps conserve cash while continuing targeted development activities over the medium term.
Bears Say
No RevenueZero reported revenue over multiple years shows lack of commercial traction and means the business cannot self-fund operations. Dependence on external capital makes the company sensitive to funding cycles and investor appetite, a persistent risk until a product reaches the market or generates recurring sales.
Sustained Cash BurnLarge, recurring negative operating cash flow erodes resources and necessitates frequent financing. This persistent cash burn materially shortens runway, forces dilution or financing events, and constrains long-term planning—creating a structural funding pressure until cash flows reverse or significant capital is secured.
Shrinking Equity And AssetsRapid depletion of equity and assets reflects cumulative losses and cash consumption, reducing the balance-sheet buffer that absorbs shocks. This structural deterioration increases insolvency and funding risk and weakens the company's ability to support larger clinical programs or unexpected costs without external capital.
GUARD FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was kr0.88 and its highest was kr27.00 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is kr31.26M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is Aug 20, 2026 which is in 63 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on May 11, 2026. The company reported -kr0.315 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.315.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -kr0.315 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in SE:GUARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―